Inventiva マネジメント

マネジメント基準チェック /24

Inventivaの CEO はFrederic Crenで、 Jan2011年に任命され、の在任期間は 13.83年です。の年間総報酬は€ 1.00Mで、 30.4%給与と69.6%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の6.45%を直接所有しており、その価値は€ 13.72M 。経営陣と取締役会の平均在任期間はそれぞれ8.2年と7.8年です。

主要情報

Frederic Cren

最高経営責任者

€1.0m

報酬総額

CEO給与比率	30.4%
CEO在任期間	13.8yrs
CEOの所有権	6.4%
経営陣の平均在職期間	8.2yrs
取締役会の平均在任期間	7.8yrs

経営陣の近況

Shareholders May Not Be So Generous With Inventiva S.A.'s (EPA:IVA) CEO Compensation And Here's Why

Jun 14

Recent updates

Inventiva S.A. (EPA:IVA) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely

Sep 27

More Unpleasant Surprises Could Be In Store For Inventiva S.A.'s (EPA:IVA) Shares After Tumbling 28%

Jun 18

Shareholders May Not Be So Generous With Inventiva S.A.'s (EPA:IVA) CEO Compensation And Here's Why

Jun 14

Optimistic Investors Push Inventiva S.A. (EPA:IVA) Shares Up 27% But Growth Is Lacking

Mar 19

CEO報酬分析

Inventiva の収益と比較して、Frederic Cren の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	n/a	n/a	-€104m
Mar 31 2024	n/a	n/a	-€107m
Dec 31 2023	€1m	€305k	-€110m
Sep 30 2023	n/a	n/a	-€95m
Jun 30 2023	n/a	n/a	-€80m
Mar 31 2023	n/a	n/a	-€67m
Dec 31 2022	€878k	€300k	-€54m
Sep 30 2022	n/a	n/a	-€55m
Jun 30 2022	n/a	n/a	-€56m
Mar 31 2022	n/a	n/a	-€56m
Dec 31 2021	€929k	€299k	-€50m
Sep 30 2021	n/a	n/a	-€45m
Jun 30 2021	n/a	n/a	-€41m
Mar 31 2021	n/a	n/a	-€36m
Dec 31 2020	€388k	€267k	-€34m
Sep 30 2020	n/a	n/a	-€29m
Jun 30 2020	n/a	n/a	-€25m
Mar 31 2020	n/a	n/a	-€27m
Dec 31 2019	€374k	€243k	-€30m
Sep 30 2019	n/a	n/a	-€34m
Jun 30 2019	n/a	n/a	-€37m
Mar 31 2019	n/a	n/a	-€35m
Dec 31 2018	€376k	€243k	-€33m
Sep 30 2018	n/a	n/a	-€29m
Jun 30 2018	n/a	n/a	-€25m
Mar 31 2018	n/a	n/a	-€22m
Dec 31 2017	€372k	€243k	-€19m

報酬と市場: Fredericの総報酬 ($USD 1.05M ) は、 French市場 ($USD 458.29K ) の同規模の企業の平均を上回っています。

報酬と収益: Fredericの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Frederic Cren (58 yo)

13.8yrs

在職期間

€1,003,699

報酬

Mr. Frederic Cren has been Chief Executive Officer of Inventiva S.A. since co-founding Inventiva S.A. in 2011. Mr. Cren has been Chairman at Inventiva S.A. since May 31, 2016. He served as President of Inv...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Frederic Cren	Co-Founder	13.8yrs	€1.00m	6.45% € 13.7m
Pierre Broqua	Co-Founder	13.8yrs	€938.43k	4.46% € 9.5m
Jean Volatier	Deputy GM & CFO	12.3yrs	データなし	0.17% € 366.3k
Alice Roudot-Ketelers	Chief Operating Officer	1.8yrs	データなし	0.017% € 36.7k
Eric Duranson	General Counsel	3.3yrs	データなし	0.017% € 36.7k
Nathalie Harroy	Head of Human Resources	12.8yrs	データなし	0.075% € 160.6k
Kristina Meyer	Executive VP and Business Development & Alliance Management	no data	データなし	データなし
Michael Cooreman	Chief Medical Officer	4.1yrs	データなし	0.017% € 36.7k
Pascaline Clerc	Executive Vice President of Strategy & Corporate Affairs	1.1yrs	データなし	0.0086% € 18.3k

8.2yrs

平均在職期間

57.5yo

平均年齢

経験豊富な経営陣: IVAの経営陣は経験豊富で経験豊富です（平均在職期間は8.2年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Frederic Cren	Co-Founder	8.5yrs	€1.00m	6.45% € 13.7m
Pierre Broqua	Co-Founder	8.5yrs	€938.43k	4.46% € 9.5m
Chris Buyse	Independent Director	7.8yrs	€61.20k	0% € 0
Annick Schwebig	Independent Director	7.8yrs	€61.20k	0.0035% € 7.5k
Jean-Louis Junien	Chairman of Scientific Advisory Board	no data	€16.00k	データなし
Xiaoqin Lu	Independent Director	6.5yrs	€43.20k	データなし
Heinz Maeusli	Independent Director	5.5yrs	€49.20k	データなし
Sven Francque	Member of Scientific Advisory Board	no data	データなし	データなし
Manal Abdelmalek	Member of Scientific Advisory Board	no data	データなし	データなし
Kenneth Cusi	Member of Scientific Advisory Board	no data	データなし	データなし
Glen Clack	Member of Scientific Advisory Board	no data	データなし	データなし
Gérard Zalcman	Scientific Advisory Board Member	no data	データなし	データなし

7.8yrs

平均在職期間

61yo

平均年齢

経験豊富なボード: IVAの取締役会は経験豊富であると考えられます ( 7.8年の平均在任期間)。

Inventiva マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Shareholders May Not Be So Generous With Inventiva S.A.'s (EPA:IVA) CEO Compensation And Here's Why

Inventiva S.A., Annual General Meeting, Jan 25, 2023

Inventiva Announces Lucy Lu as the Director of its Board of Directors

Insufficient new directors

Insufficient new directors

Inventiva S.A., Annual General Meeting, May 19, 2022

Recent updates

Inventiva to Present Data from the Final Analysis of the Phase 2 Study Evaluating the Combination of Lanifibranor with Empagliflozin in Patients with Mash and T2d At the Aasld the Liver Meeting® Late-Breaker Session

Inventiva Announces the Positive Recommendation of the Fifth DMC of the Nativ3 Phase 3 Clinical Trial with Lanifibranor in Patients with Mash

New major risk - Shareholder dilution

Consensus revenue estimates increase by 81%, EPS downgraded

Inventiva S.A. announced that it expects to receive €348 million in funding from a group of investors

Price target decreased by 9.0% to €9.68

Consensus EPS estimates upgraded to €1.21 loss, revenue downgraded

Inventiva S.A. (EPA:IVA) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely

First half 2024 earnings released: €0.94 loss per share (vs €1.32 loss in 1H 2023)

Price target decreased by 20% to €10.64

Consensus revenue estimates increase by 113%

More Unpleasant Surprises Could Be In Store For Inventiva S.A.'s (EPA:IVA) Shares After Tumbling 28%

Shareholders May Not Be So Generous With Inventiva S.A.'s (EPA:IVA) CEO Compensation And Here's Why

Consensus revenue estimates decrease by 67%

Inventiva Announces the Publication in Nature Communications of Additional Results from Native Phase IIb Clinical Trial Demonstrating Improvement of Markers of Cardiometabolic Health in Patients with MASH/NASH Treated with Lanifibranor

Consensus revenue estimates decrease by 21%

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Optimistic Investors Push Inventiva S.A. (EPA:IVA) Shares Up 27% But Growth Is Lacking

New minor risk - Share price stability

Inventiva S.A. Provides Update on its Clinical Trial NATiV3

Some Confidence Is Lacking In Inventiva S.A.'s (EPA:IVA) P/S

Consensus EPS estimates fall by 13%

Forecast to breakeven in 2026

Inventiva S.A. to Report First Half, 2024 Results on Sep 25, 2024

Price target decreased by 14% to €15.35

Inventiva Announces the Randomization of the First Patient in China in the NATiV3 Clinical Trial and Provides an Update on Its Clinical Development Program

Price target decreased by 7.4% to €16.50

New major risk - Negative shareholders equity

First half 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates increase by 216%

New major risk - Negative shareholders equity

Consensus revenue estimates decrease by 78%

New major risk - Financial position

New minor risk - Shareholder dilution

Consensus revenue estimates decrease by 19%

Inventiva S.A. to Report Fiscal Year 2023 Results on Mar 27, 2024

Consensus revenue estimates increase by 573%

Inventiva S.A. to Report Nine Months, 2023 Results on Sep 28, 2023

New major risk - Revenue and earnings growth

Price target increased by 15% to €18.76

Inventiva Announces Positive Topline Results from the Investigator-Initiated Phase Ii Clinical Trial Evaluating Lanifibranor in Patients with T2d and NAFLD

Analyst Forecasts Just Became More Bearish On Inventiva S.A. (EPA:IVA)

Consensus revenue estimates decrease by 15%

Pinning Down Inventiva S.A.'s (EPA:IVA) P/S Is Difficult Right Now

Consensus revenue estimates decrease by 37%

Revenue Downgrade: Here's What Analysts Forecast For Inventiva S.A. (EPA:IVA)

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Forecast to breakeven in 2025

Inventiva S.A. to Report Fiscal Year 2022 Results on Mar 29, 2023

Inventiva S.A. Announces Changes to the Clinical Development of Lanifibranor, Including Plans for New Phase III Trial in Patients with NASH and Compensated Cirrhosis

Inventiva S.A. Announces Changes to the Clinical Development of Lanifibranor, Including Plans for New Phase III Trial in Patients with NASH and Compensated Cirrhosis

Inventiva S.A., Annual General Meeting, Jan 25, 2023

Inventiva Announces Lucy Lu as the Director of its Board of Directors

Insufficient new directors

Inventiva Provides Update on Development of cedirogant by AbbVie

Consensus revenue estimates increase by 10%

Consensus revenue estimates increase by 352%

First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Inventiva S.A. to Report First Half, 2022 Results on Sep 21, 2022

Inventiva Announces the Screening of the First Patient in LEGEND , Phase IIa Combination Trial with Lanifibranor and Empagliflozin in Patients with NASH and T2D

Despite Lacking Profits Inventiva (EPA:IVA) Seems To Be On Top Of Its Debt

Price target decreased to €19.96

Inventiva Announces Three Scientific Presentations At the EASL International Liver Congress™ 2022

Insufficient new directors

Consensus forecasts updated

No longer forecast to breakeven

Inventiva S.A., Annual General Meeting, May 19, 2022

Inventiva S.A. Announces IND Application for the Phase Ii Combination Trial with Lanifibranor and Empagliflozin in Patients with Nash

Forecast to breakeven in 2024

マネジメント基準チェック /24